Chargement...

Robocath’s joint venture, Cathbot, concludes first clinical study in China to evaluate robotic PCI safety and efficacy

20 July 2022
End of study brings Robocath closer to commercializing R-One in China in 2023 149 patients enrolled over six months in four Chinese centers Results of first vascular robotics study on this scale in China will be published in March 2023

 

Rouen, France, July 20 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that its joint venture, Cathbot, established in 2020…

Learn more

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

18 May 2022
100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure

 

Rouen, France, May 18, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution clinical study at the international EuroPCR conference. The study, which included 62 patients across six European centers,…

Learn more

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

11 January 2022

Study results will be presented at EuroPCR conference in Paris, France, May 2022.

Rouen, France, January 11, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study.

The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the university hospitals in Rouen and Caen with Prof. Durand…

Learn more

Robocath successfully completes first robotic coronary angioplasty with R-One™ in China

30 November 2021

Rouen, France, November 30, 2021 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today announces the successful completion of the first coronary angioplasty in China assisted by its R-One™ robotic platform. The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications.

This robotic assisted procedure is the first intervention within a clinical…

Learn more

Robocath successfully performs first carotid stenting in France with R-One™ robot at Rennes University Hospital

24 November 2021

Rouen, France, November 24, 2021 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today its successful first robotic carotid stenting at Rennes University Hospital. This breakthrough in the neurovascular field was performed on November 16, using Robocath’s R-One robot, operated by Dr. François Eugène and his team.

The procedure is part of a clinical study, which is the first stage of an ambitious research program launched last July by…

Learn more

Robocath and Rennes University Hospital launch co-development research program into treatment of strokes in partnership with Philips France

7 July 2021

Rouen and Rennes, France, July 7, 2021 – Robocath, a company that designs, develops and commercializes robotic solutions to treat cardiovascular diseases, and Rennes University Hospital, today announce the launch of a co-development research program using robotics to improve treatment for stroke victims.

With the support of Philips France, this unique program will be implemented over the next four years. It will focus on the use of robotics in treating strokes, the second most common cause of death…

Learn more

Robocath successfully completes first robotic coronary angioplasties in Belgium

4 May 2021

Rouen, France, May 04, 2021 – Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional cardiologist at ZNA Middelheim hospital in Antwerp, and his team.  Robotic-assisted PCI has never been done before in this country.

R-One is…

Learn more

Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty

12 January 2021

Rouen, France, January 13, 2021 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in France – spanning 75 miles (120 km) between the two locations. The procedure is the first of its kind…

Learn more

Robocath bolsters Strategic Committee with appointment of Chantal Le Chat as independent member

14 December 2020

Rouen, France, December 14, 2020 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces that it has appointed Chantal Le Chat as an independent member of the Strategic Committee.

Chantal boasts 35 years of skill and know-how built up while working a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including…

Learn more

Robocath finalizes creation of the joint venture with MicroPort through its medical robotic subsidiary MedBot

2 November 2020

Rouen, France, November 2, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces creation of the joint venture with MicroPort Scientific Corporation ‘MicroPort’, through ‘MedBot’, its MicroPort MedBot (Shanghai) Co. Ltd subsidiary. This strategic partnership will enable the commercialization in China of its first robotic-assisted platform, R-One™. Both companies will also carry out research and development activities as agreed per the terms of the investment announced in April…

Learn more
Subscribe to our newsletter